We have no doubt about the benefits that medical cannabis has on various illnesses and diseases. There is good evidence in robust human clinical trials that cannabis is of benefit for a variety of ailments whether they be physical, mental, or social.
Cannabis Industrial Marketplace is your equipment & supply information hub, aiding you with knowledge about growing and cultivation equipment, dispensary supplies and everything in between. Equipping you with up to date news about upcoming elections, tips on marketing, and specific state laws.
Researchers have made great strides in discovering how medical cannabis works in the body, but individual patients may still wonder how it can help them, and in what form and what dose. The journey to figuring out the answer can be frustrating, as even experienced medical cannabis consumers often don’t know the specifics when it comes to questions of what, how, when, and how much.
The answer has to do with bioavailability, the fraction of an active ingredient that gets to the target cells after the body metabolizes it and breaks it down.
For example, if you take a single 500 milligram tablet of acetaminophen, it goes into your stomach, where the active ingredient is digested. It goes through the liver, where it interacts with enzymes and some of it is deactivated, or destroyed. By the time it reaches the bloodstream, only about 315 mg, or 63 percent, is left to do the job.
Companies take this into account when coming up with dosing guides, and medical professionals come out of school armed with reference books telling them how bioavailable various drugs will be. To confuse matters more, the amount left after metabolism can change based on how large the dose is, what else the liver is doing, and other body-specific factors.
Cannabinoids, of course, are not listed in these reference works, but the body of evidence in modern research serves as a helpful guide.
In general, cannabinoids act as signaling messengers that enter the body and bind to cellular receptors. From there, they set off a chain of events, including changes in protein concentrations and metabolite levels, and ultimately create physiological changes in the body. Those are the desired effects, as well as the side effects.
How big those effects are depends on the number and “fit” of the signaling molecules.
When a cannabis product is labeled, for example, 5 percent THC, we would like to know how much of that 5 percent interacts with its target in the body — in this case, the cannabinoid-binding receptors. Knowing the bioavailability, or fraction of a drug that gets absorbed, helps us to predict the expected effects, such as reduced pain or improved sleep.
To more accurately gauge the effects of cannabis, it’s important to understand two basic concepts. First, we’ll look at how the various paths cannabis can take into the body impact its bioavailability. In a follow-up column, we’ll discuss how cannabis moves through the body, and what happens to it there.
Paths Into the Body
Traditional pharmaceuticals are listed by dosage type: oral, intravenous, intramuscular, and so on. Cannabinoids are available in several different forms, delivery methods, and combinations of the two that affect their path into the body.
In terms of active ingredients, we can classify cannabis products into three types:
- Single-molecule, or pure, products, such as those containing only THC or CBD
- Mixtures, with more than one known molecule, such as THC/CBD/terpene blends, provided at a specific ratio
- Flower, which contains hundreds of molecules, some of which may or may not be specified
We do not expect a product with 20 percent pure THC, a product with 20 percent THC in a THC/CBD mixture, and a flower labeled as 20 percent THC to produce the same results in the body, because these products do not have the same bioequivalence, a pharmaceutical term indicating products with identical effects. The single-molecule product will interact with a specific type of receptor in the body, while the mixture and flower will have an “entourage effect” in which multiple molecules or the whole plant work together to create a different response from that of the purified active ingredient, according to research from neurologist and cannabis researcher Dr. Ethan Russo.
The form of the product and the delivery method both affect bioequivalence, meaning they both raise the question of “how much?” For example, flower labeled 20 percent THC may also contain significant amounts of THCA, the cannabinoid acid form that must be converted to THC by heat, which increases the total THC concentration delivered to the body to as much as 25 percent.
Another challenge for determining how much is inaccurate potency labeling. A 2017 study led by Dr. Marcel O. Bonn-Miller found that only one-third of the CBD extracts sold online are accurately labeled, with large numbers of products containing either significantly more or significantly less CBD than stated on the label. This study indicated that vaporization liquid is the most frequently mislabeled product.
As states roll out rules and regulations for lab testing, many are discovering variances in labeling, lab procedures and allowable levels of contaminants that led to significant failure rates. A report from NBC’s San Francisco Bay Area affiliate KNTV-TV showed that identical samples tested in two independent labs could result in a 23 percent difference in content, which shows a lack of testing reproducibility among labs.
For comparison, pharmaceutical companies report a maximum of 5 percent variation of active ingredient content among products from the same batch.
Standardization of production processes and testing, as well as increased regulation, should lead to greater accuracy.
This article was first published on https://www.cannabisimp.com.